Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |Streptavidin（SA） Hot |Claudin 18.2 |Cadherin-17 
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TrkB

TrkB

Brief Information

Name:Neurotrophic tyrosine kinase receptor type 2
Target Synonym:EC:2.7.10.1,Tropomyosin-related kinase B,Trk-B,GP145-TrkB,NTRK2,Neurotrophic Tyrosine Kinase Receptor Type 2,TRKB,BDNF-Tropomyosine Receptor Kinase B,BDNF/NT-3 Growth Factors Receptor,Tyrosine Kinase Receptor B,TrkB Tyrosine Kinase,EC 2.7.10.1,OBHD,Receptor, trkB,Neurotrophic Receptor Tyrosine Kinase 2,Neurotrophic Tyrosine Kinase, Receptor, Type 2,EIEE58,EC 2.7.10
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CHEK-ATP082 Human HEK293/Human TrkB Stable Cell Line
NT2-H5228 Human Human TrkB / NTRK2 Protein, His Tag
NT2-H5228-structure
NT2-H5228-sds
NT2-H5254 Human Human TrkB / NTRK2 Protein, Fc Tag
NT2-H5254-structure
NT2-H5254-sds
ACRO Quality

Part of Bioactivity data

NT2-H5254-ELISA
TrkB ELISA

Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 2 μg/mL (100 μL/well) can bind Human TrkB, Fc Tag (Cat. No. NT2-H5254) with a linear range of 1-20 ng/mL (Routinely tested).

Protocol
NT2-H5228-ELISA
TrkB ELISA

Immobilized Human BDNF, premium grade (Cat. No. BDF-H5219) at 1 μg/mL (100 μL/well) can bind Human TrkB, His Tag (Cat. No. NT2-H5228) with a linear range of 2-78 ng/mL (Routinely tested).

Protocol

Synonym Name

NTRK2,TRKB,GP145-TrkB

Background

Neurotrophic tyrosine kinase receptor type 2 (NTRK2) is also known as BDNF/NT-3 growth factors receptor, Tropomyosin-related kinase B (TRKB) and TrkB tyrosine kinase, which belongs to the protein kinase superfamily or Tyr protein kinase family. Insulin receptor subfamily. NTRK2 / TrkB contains two Ig-like C2-type (immunoglobulin-like) domains, two LRR (leucine-rich) repeats, one LRRCT domain, one LRRNT domain, one protein kinase domain. NTRK2 / Trk-B is expressed in the central and peripheral nervous system. The catalytic activity of NTRK2 is ¡°ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate¡±. NTRK2 / TrkB involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Entrectinib NMS-E628; RXDX-101; RG-6268 Approved Nerviano Medical Sciences Srl Rozlytrek, 罗圣全 Japan Carcinoma, Non-Small-Cell Lung Chugai Pharmaceutical Co Ltd 2019-06-18 Cholangiocarcinoma; Melanoma; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Glioma; Leukemia, Myeloid, Acute; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Colorectal Neoplasms; Hepatic Insufficiency; Breast Neoplasms; Brain Neoplasms; Solid tumours; Sarcoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Pancreatic Neoplasms; Salivary Gland Neoplasms; Neoplasms; Carcinoma, Renal Cell; Hematologic Neoplasms; Skin Melanoma; Ovarian Neoplasms; Head and Neck Neoplasms Details
Larotrectinib sulfate LOXO-101; ARRY-470; BAY-2757556 Approved Array Biopharma Vitrakvi, 维泰凯 United States Solid tumours Bayer Healthcare 2018-11-26 Glioma; Central Nervous System Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Histiocytosis, Langerhans-Cell; Cholangiocarcinoma; Osteosarcoma; Sarcoma, Ewing; Neuroblastoma; Sarcoma; Histiocytic Sarcoma; Colorectal Neoplasms; Neoplasms, Neuroepithelial; Urinary Bladder Neoplasms; Thyroid Neoplasms; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Uterine Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Neoplasms, Germ Cell and Embryonal; Melanoma; Neuroectodermal Tumors, Primitive, Peripheral; Xanthogranuloma, Juvenile; Squamous Cell Carcinoma of Head and Neck; Solid tumours; Ependymoma; Medulloblastoma; Liver Neoplasms; Fibrosarcoma; Leukemia; Rhabdomyosarcoma; Hematologic Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms; Hepatoblastoma; Rhabdoid Tumor; Rectal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Wilms Tumor; Colonic Neoplasms; Ski Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx United States Carcinoma, Neuroendocrine; Thyroid Neoplasms Exelixis Inc 2012-11-29 Urethral Neoplasms; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Gliosarcoma; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Peritoneal Neoplasms; Bile Duct Neoplasms; Sarcoma, Clear Cell; Uterine Neoplasms; Adenocarcinoma, Clear Cell; Sarcoma, Ewing; Carcinoma, Adenosquamous; Breast Neoplasms; Neurofibroma, Plexiform; Osteosarcoma; Prostatic Neoplasms; Sarcoma; Medullary thyroid cancer (MTC); Carcinoma, Hepatocellular; Melanoma; Paraganglioma; Meningioma; Neoplasms, Germ Cell and Embryonal; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Endometrioid; Thyroid Cancer, Papillary; Brain Neoplasms; Carcinoma, Neuroendocrine; Sarcoma, Alveolar Soft Part; Lymphoma; Fallopian Tube Neoplasms; Brain metastases; Glioma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Carcinoid Tumor; Glioblastoma; Skin Neoplasms; Neoplasms; Carcinoma, Papillary; Hepatoblastoma; Pheochromocytoma; Pain; Rejection of liver transplantation; Carcinoma, Renal Cell; Pancreatic neuroendocrine tumors Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lestaurtinib SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 Phase 3 Clinical Kyowa Hakko Kirin Co Ltd Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details
Merestinib 5OGS5K699E; LY-2801653 Phase 2 Clinical Eli Lilly And Company Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung Details
ACD-856 ACD-856 Phase 1 Clinical Alzecure Pharma Ab Alzheimer Disease; Cognition Disorders Details
HG-030 HG-030 Phase 1 Clinical Hitgen Inc Solid tumours Details
FB-1001 FB_-1001; FB-1001; FB1001 Phase 1 Clinical 4b Technologies (Suzhou) Ltd Optic Nerve Diseases; Glaucoma Details
BrAD-R13 BrAD-R13; BrADR13 Phase 1 Clinical Shanghai Braegen Pharmaceutical Co Ltd Alzheimer Disease Details
PBI-200 PBI-200 Phase 1 Clinical Pyramid Biosciences Solid tumours; Desmoplastic Small Round Cell Tumor; Brain Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap